| NCT06991114 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | RECRUITING | PHASE2 | 2025-07-09 | 2029-01 | 2028-01 |
| NCT06265220 | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | RECRUITING | PHASE1 | 2024-04-03 | 2027-08 | 2027-08 |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | WITHDRAWN | PHASE1, PHASE2 | 2023-08-01 | 2027-04 | 2027-04 |
| NCT04673617 | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-03-29 | 2025-12-31 | 2024-08-31 |